Dipyridamole-thallium imaging: minimum dose requirements.
A total of 372 consecutive dipyridamole-thallium studies were reviewed to determine if a relationship existed between the dose of dipyridamole administered and the likelihood that thallium images would show reversible defects. Men who received a dose of less than 31 mg were less likely to have thallium redistribution (P = 0.0001). Until the ideal study involving repeat testing with incremental dipyridamole doses on different days is carried out, the authors recommend that a minimal dose of 31 mg be administered for dipyridamole-thallium imaging.
Department of Medicine, Maisonneuve Hospital, Montreal, Quebec.
C
C
LaBonté
J
J
Lette
M
M
Cerino
A
A
Gagnon
D
D
Waters
D003331:Coronary Vessels / Q000187:drug effects; D004176:Dipyridamole / Q000008:administration & dosage*; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D013794:Thallium Radioisotopes
D013794:Thallium Radioisotopes; D004176:Dipyridamole